Axial Biotherapeutics to Present Virtual Presentation at American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting

WALTHAM, Mass., May 22, 2020 – Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced the upcoming virtual presentation on the development of novel therapeutics focused on treating Central Nervous System (CNS) indications via the gut-brain axis at the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting being held May 29-30, 2020.

Virtual Presentation Details:

Title: Harnessing the gut-brain axis to develop novel Central Nervous System (CNS) therapeutics to improve the quality of life for people with CNS diseases and disorders

Presenter: David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics

Session Title: Pharmaceutical Pipeline Session

Date and Time: Saturday, May 30, 2020 from 4:25-4:35 PM ET

About Axial Therapeutics

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurological diseases. Axial is advancing a pipeline of small molecule product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD), and additional preclinical initiatives in small molecules in other areas of autism and PD, as well as oncology and rare CNS diseases.

Contacts for Axial Therapeutics


Mike Beyer
Sam Brown, Inc.


Jeffrey Young, CFO